Argenica Therapeutics (AGN) H1 2026 earnings summary

Executive summary

• Focused on research and development of a neuroprotective therapeutic drug, with ongoing Phase 2 trial of ARG-007 in ischaemic stroke patients and non-clinical studies for other indications.

• Loss after income tax for the half-year ended 31 December 2025 was $3,816,831, compared to $1,187,221 for the same period last year.

• Revenue comprised $93,430 in interest income and $626,739 in government grant income, with a significant reduction in R&D tax incentive rebate due to timing differences.

Financial highlights

• Total income for the half-year was $720,169, down from $3,107,366 in the prior year, mainly due to lower R&D tax incentive rebate recognition.

• Research and development costs increased slightly to $3,032,222 from $2,916,679 year-over-year.

• Net operating cash outflows were $5,514,842, up from $1,177,279 in the prior year, reflecting timing of R&D tax rebate receipts.

• Cash and cash equivalents at 31 December 2025 were $5,037,373, down from $10,555,160 at 30 June 2025.

• Net assets at 31 December 2025 were $3,443,280, compared to $7,237,271 at 30 June 2025.

Outlook and guidance

• The company is dependent on successful clinical, regulatory, and funding milestones for future progress.

• No dividend is recommended for the half-year ended 31 December 2025.